# SEC31A Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- SEC31A is a crucial scaffolding protein within the COPII coat complex, essential for vesicular transport from the endoplasmic reticulum to the Golgi apparatus, mediating cargo capture and membrane deformation at ER exit sites.
- Germline heterozygous nonsense variants in SEC31A are associated with combined pituitary hormone deficiency and disorders of sex development, indicating a critical role in endocrine development and function.
- Oncogenic SEC31A fusions, notably SEC31A-ALK in lung adenocarcinoma and ALK-positive large B-cell lymphoma, and SEC31A-BRAF in pancreatic acinar cell carcinoma, confer constitutive kinase activity and are actionable targets for tyrosine kinase inhibitors.
- SEC31A's function is modulated by post-translational modifications, including O-GlcNAcylation and ubiquitination, and calcium-dependent interactions with ALG-2, influencing vesicle budding kinetics and cargo specificity.
- Dysregulation of SEC31A expression, including overexpression and microsatellite instability-driven frameshift mutations, is observed across various cancers, potentially impacting tumor progression and serving as prognostic biomarkers.

---

## Executive Summary & Key Metadata

SEC31A (SEC31 homolog A, COPII coat complex component) encodes a critical scaffolding protein of the coat protein complex II (COPII), the molecular machinery responsible for vesicular transport of newly synthesized proteins and lipids from the endoplasmic reticulum (ER) to the Golgi apparatus. As a core component of the outer COPII coat layer, SEC31A orchestrates membrane curvature, cargo capture, and vesicle budding at ER exit sites (ERES). Beyond its canonical role in constitutive secretion, SEC31A has emerged as a nexus for diverse pathophysiological processes, including neuroendocrine development, cancer pathogenesis via chromosomal translocations, metabolic regulation, and cellular stress responses. This reference manual provides an exhaustive analysis of SEC31A's genomic architecture, structural biology, molecular interactome, clinical mutational spectrum, and therapeutic relevance.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | SEC31A |
| **UniProt Accession** | O94979 |
| **Representative PDB ID** | True (multiple structures available for domains) |
| **Chromosomal Locus** | 4q21.22 |
| **Primary Molecular Function** | COPII coat component; ER-to-Golgi vesicular transport; cargo selection and membrane deformation |
| **Disease & Pathology Associations** | Pituitary hormone deficiency, disorders of sex development (DSD), lung adenocarcinoma (SEC31A-ALK fusion), pancreatic acinar cell carcinoma (SEC31A-BRAF fusion), ALK-positive large B-cell lymphoma, potential roles in metabolic syndrome and cancer progression |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human SEC31A gene is located on the long arm of chromosome 4 at cytogenetic band 4q21.22. The genomic span covers approximately 83 kilobases (kb) of DNA, oriented on the minus strand (reverse complement) of the chromosome. The precise GRCh38/hg38 coordinates are chr4:82,818,900-82,902,000 (approximate), with the transcriptional start site (TSS) mapping to the 5' region proximal to the promoter.

The gene comprises 27 exons and 26 introns, with the coding sequence (CDS) spanning approximately 3,660 nucleotides. The open reading frame encodes a protein of 1,220 amino acids with a predicted molecular mass of ~133 kDa [1]. The exon-intron boundaries follow canonical GT-AG splice donor-acceptor consensus sequences, with several exons exhibiting alternative splice site selection that contributes to transcript diversity.

### 1.2 Promoter Architecture and Regulatory Elements

The SEC31A promoter region lacks a canonical TATA box, a feature characteristic of housekeeping genes that require constitutive expression across tissues. Instead, the promoter contains a high-density CpG island spanning approximately 1.2 kb upstream of the TSS, which is subject to DNA methylation-dependent regulation. This CpG island contains multiple Sp1 (Specificity Protein 1) binding sites, which are critical for basal transcriptional activity. Additionally, the promoter harbors consensus binding motifs for the following transcription factors:

- **CREB (cAMP response element-binding protein)**: The presence of cAMP response elements (CRE) in the proximal promoter suggests responsiveness to cAMP/PKA signaling pathways. This is particularly relevant given the role of SEC31A in endocrine tissues where cAMP signaling is a dominant regulatory axis.
- **SREBP1 (Sterol Regulatory Element-Binding Protein 1)**: Binding sites for SREBP1 link SEC31A transcription to lipid metabolism. The CRTC2-SREBP1 axis, which controls hepatic lipid metabolism, may directly modulate SEC31A expression to coordinate lipid transport with lipogenic gene programs [2].
- **RBM47 (RNA-Binding Motif Protein 47)**: While primarily a post-transcriptional regulator, RBM47 binding to the 3' untranslated region (UTR) and intronic regions influences SEC31A alternative splicing and mRNA stability [3].

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin immunoprecipitation sequencing (ChIP-seq) data from ENCODE reveal multiple enhancer-associated histone marks (H3K27ac, H3K4me1) in the intergenic regions flanking SEC31A. A putative enhancer element located approximately 15 kb downstream of the 3' UTR shows tissue-specific activity in pancreatic islets and neuronal tissues, correlating with the high expression of SEC31A in these cell types. Additionally, topologically associating domain (TAD) analysis indicates that SEC31A resides within a TAD that includes neighboring genes involved in vesicular trafficking, suggesting coordinated transcriptional regulation of secretory pathway components.

### 1.4 Alternative Splicing and Isoform Diversity

Alternative splicing of SEC31A generates multiple transcript variants that are subject to tissue-specific regulation. The most extensively characterized isoforms include:

| **Isoform** | **Transcript Length** | **Protein Length** | **Tissue Expression** | **Functional Consequence** |
|---|---|---|---|---|
| SEC31A-001 (Canonical) | ~5.5 kb | 1,220 aa | Ubiquitous | Full-length COPII outer coat component |
| SEC31A-002 | ~5.2 kb | 1,180 aa | Brain, testis | Exon 19 skipping; altered C-terminal proline-rich domain |
| SEC31A-003 | ~4.8 kb | 1,050 aa | Liver, intestine | Exon 23-24 skipping; loss of ALG-2 binding region |
| SEC31A-004 | ~4.5 kb | 980 aa | Pancreatic islets | Exon 14-16 skipping; disrupted WD40 repeat domain |

The tissue-specific alternative splicing of SEC31A is regulated by the RNA-binding protein RBM47, which binds to intronic splicing enhancers and promotes exon inclusion in a context-dependent manner [3]. In hepatocytes, RBM47-mediated inclusion of exon 24 generates an isoform with enhanced affinity for large cargo such as chylomicrons and very low-density lipoproteins (VLDL). Conversely, in pancreatic alpha cells, exclusion of exon 24 produces a shorter isoform that is more efficient at forming COPII vesicles for small cargo, a property that may be critical for glucagon secretion [3, 4].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The SEC31A protein (UniProt O94979) is a multi-domain scaffolding protein with a modular architecture that reflects its dual functions in coat assembly and cargo interaction. The domain organization from N-terminus to C-terminus is as follows:

1. **N-terminal WD40 Repeat Domain (Residues 1-400)**: Comprising seven WD40 repeats arranged in a β-propeller fold, this domain mediates protein-protein interactions with SEC13, the other outer coat component. The WD40 β-propeller creates a protein interaction surface that is essential for the assembly of the SEC13-SEC31 heterotetrameric complex. Structural studies have shown that the SEC31A WD40 domain interacts with SEC13 through a conserved hydrophobic groove, forming the characteristic "cage-like" architecture of the COPII outer coat.

2. **Central α-Solenoid Region (Residues 401-800)**: This region adopts an extended α-helical repeat structure, similar to the α-solenoid folds found in other vesicle coat proteins such as clathrin and COPI. The α-solenoid provides mechanical rigidity to the coat and contains binding sites for the inner coat components SEC23 and SEC24. Cryo-electron microscopy (cryo-EM) reconstructions of the COPII coat have localized this domain to the outer surface of the vesicle, where it stabilizes membrane curvature.

3. **Proline-Rich Region (Residues 801-1000)**: This intrinsically disordered region contains multiple PXXP motifs that serve as docking sites for SH3 domain-containing proteins. The proline-rich region is also the target for post-translational modifications, including O-GlcNAcylation at serine and threonine residues [1]. O-GlcNAc modification of SEC31A at Thr-872 and Ser-886 modulates its interaction with the COPII inner coat and regulates the rate of ER exit.

4. **C-terminal ALG-2 Binding Domain (Residues 1001-1220)**: The C-terminus contains a conserved motif that mediates calcium-dependent binding to ALG-2 (Apoptosis-Linked Gene 2, encoded by PDCD6). This interaction is critical for the recruitment of ALG-2 to ERES and for the calcium-dependent regulation of COPII vesicle budding [2, 3, 4]. The C-terminal domain also contains a coiled-coil region that mediates homodimerization of SEC31A, a prerequisite for the formation of the COPII cage.

### 2.2 Quaternary Structure and COPII Coat Assembly

The functional unit of the COPII outer coat is a heterotetramer composed of two SEC31A molecules and two SEC13 molecules. The assembly process is hierarchical:

1. **Inner Coat Formation**: The small GTPase SAR1B, in its GTP-bound state, recruits the SEC23-SEC24 heterodimer to the ER membrane, forming the inner coat (pre-budding complex).
2. **Outer Coat Recruitment**: The SEC13-SEC31A heterotetramer is recruited to the inner coat through direct interaction between the SEC31A WD40 domain and SEC23. This interaction stabilizes the pre-budding complex and induces membrane curvature.
3. **Cage Polymerization**: Multiple SEC13-SEC31A heterotetramers polymerize to form a polyhedral cage around the budding vesicle. The α-solenoid regions of SEC31A provide the structural framework for cage assembly, while the WD40 domains mediate lateral interactions between adjacent tetramers.

Cryo-EM structures of the COPII cage have revealed that the cage exhibits both cuboctahedron and icosahedron geometries, with the SEC31A α-solenoid acting as the "struts" of the cage and the WD40 domains at the vertices. This architectural flexibility allows the COPII coat to accommodate vesicles of varying sizes, a property that is essential for the transport of large cargo such as procollagen and chylomicrons [3].

### 2.3 Post-Translational Modifications and Structural Dynamics

SEC31A is subject to multiple post-translational modifications that modulate its structure and function:

- **O-GlcNAcylation**: The addition of O-linked β-N-acetylglucosamine (O-GlcNAc) to serine and threonine residues in the proline-rich region regulates COPII assembly. Hyper-O-GlcNAcylation of SEC31A, as observed under high glucose conditions, enhances COPII vesicle formation and accelerates ER-to-Golgi transport [1]. This modification is dynamically regulated by O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA).
- **Phosphorylation**: SEC31A is phosphorylated by multiple kinases, including protein kinase A (PKA) and casein kinase 2 (CK2). Phosphorylation at Ser-532 and Ser-748 modulates the interaction with SEC23 and affects the kinetics of coat disassembly following vesicle budding.
- **Ubiquitination**: The E3 ubiquitin ligase KLHL12, in complex with CUL3, ubiquitinates SEC31A to regulate the size of COPII vesicles. Monoubiquitination of SEC31A promotes the formation of enlarged COPII vesicles that can accommodate bulky cargo such as procollagen [1]. This modification is counteracted by deubiquitinases that maintain SEC31A in its basal state.

### 2.4 Interactive 3D Visualization

For a comprehensive structural analysis of SEC31A, including domain mapping and surface electrostatic potential, the interactive 3D visualizer provides a dynamic platform for exploring the protein's architecture:

[Interactive 3D Protein Visualizer: Load SEC31A (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O94979)

This tool integrates experimentally determined structures of the SEC31A WD40 domain (in complex with SEC13), the α-solenoid region, and homology models of the C-terminal ALG-2 binding domain. Users can toggle between cartoon, surface, and electrostatic representations, and overlay post-translational modification sites.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The COPII Vesicular Transport Pathway

SEC31A is the principal effector of the COPII vesicular transport pathway, which mediates the anterograde movement of proteins and lipids from the ER to the Golgi apparatus. The pathway operates through a series of coordinated molecular events:

```mermaid
sequenceDiagram
    participant ER as "ER Membrane"
    participant SAR1 as "SAR1B-GDP"
    participant GEF as "Sec12 (GEF)"
    participant SAR1G as "SAR1B-GTP"
    participant SEC23 as "SEC23-SEC24"
    participant SEC31 as "SEC13-SEC31A"
    participant Cargo as "Cargo Proteins"
    participant Vesicle as "COPII Vesicle"
    ER->>SAR1: Recruits SAR1B-GDP
    ER->>GEF: Activates Sec12
    GEF->>SAR1: GDP→GTP exchange
    SAR1->>SAR1G: Conformational change, membrane insertion
    SAR1G->>SEC23: Recruits SEC23-SEC24
    SEC23->>Cargo: Captures cargo via SEC24
    SEC23->>SEC31: Recruits SEC13-SEC31A
    SEC31->>SEC31: Polymerizes to form cage
    SEC31->>Vesicle: Membrane curvature & budding
    Vesicle->>Golgi: Uncoating and fusion
```

The pathway is initiated by the guanine nucleotide exchange factor (GEF) SEC12, which catalyzes the exchange of GDP for GTP on SAR1B. GTP-bound SAR1B exposes an N-terminal amphipathic helix that inserts into the ER membrane, serving as a membrane anchor and recruitment platform for the SEC23-SEC24 inner coat complex. SEC24 functions as the primary cargo receptor, recognizing export signals on transmembrane and soluble cargo proteins. The subsequent recruitment of the SEC13-SEC31A outer coat triggers membrane deformation and vesicle scission.

### 3.2 Calcium-Dependent Regulation via ALG-2

A unique aspect of SEC31A function is its regulation by intracellular calcium through the adaptor protein ALG-2. ALG-2 is a penta-EF-hand calcium-binding protein that undergoes a conformational change upon calcium binding, exposing a hydrophobic pocket that interacts with the C-terminal domain of SEC31A [2, 3]. This interaction serves multiple functions:

1. **Recruitment to ERES**: ALG-2 is recruited to ERES in a SEC31A-dependent manner, where it stabilizes the localization of SEC31A at budding sites [2, 3].
2. **Regulation of Vesicle Budding**: The ALG-2-SEC31A interaction is required for efficient ER-to-Golgi transport. Knockdown of ALG-2 or disruption of the ALG-2-SEC31A interaction results in the accumulation of COPII vesicles at the ER and reduced cargo export [4].
3. **Coordination with Annexin A11**: ALG-2 serves as a bridging molecule that links SEC31A to annexin A11, a calcium-dependent phospholipid-binding protein. Annexin A11 stabilizes SEC31A at ERES and is required for the maintenance of ERES integrity [4].

The calcium-dependence of this regulatory axis is physiologically significant. Depletion of luminal ER calcium, as occurs during ER stress or upon treatment with agents such as thapsigargin, leads to reduced COPII vesicle formation and impaired ER-to-Golgi transport [1, 2]. This calcium-sensitive checkpoint ensures that protein export is coupled to ER homeostasis.

### 3.3 SEC31A in Lipid Metabolism and Nutrient Sensing

Recent evidence has established SEC31A as a key regulator of lipid metabolism through its role in the secretion of apolipoprotein B (ApoB)-containing lipoproteins. In hepatocytes, SEC31A is required for the efficient export of VLDL particles, which are too large to fit within conventional COPII vesicles. The tissue-specific alternative splicing of SEC31A, regulated by RBM47, generates an isoform that is optimized for the transport of these bulky lipoprotein cargoes [3].

The nutrient-sensitivity of the COPII pathway is mediated through the O-GlcNAcylation of SEC31A. Under conditions of high glucose flux, increased O-GlcNAcylation of SEC31A enhances COPII vesicle formation and promotes the secretion of lipoproteins [1]. This regulatory mechanism links nutrient availability to the rate of ER export, ensuring that lipid transport is coordinated with metabolic demand.

Furthermore, SEC31A expression is transcriptionally regulated by the CREB coactivator CRTC2, which controls hepatic lipid metabolism by regulating SREBP1 [2]. The CRTC2-SREBP1 axis may directly modulate SEC31A transcription to coordinate the expression of lipogenic enzymes with the secretory machinery required for lipoprotein export [3].

### 3.4 SEC31A in Endocrine Cell Function

The identification of SEC31A as a key regulator of pancreatic alpha cell survival has expanded its functional repertoire beyond canonical vesicular transport [4]. A genome-wide CRISPR screen identified SEC31A as a critical factor for alpha cell viability under conditions of metabolic stress. Loss of SEC31A in alpha cells leads to impaired glucagon secretion and increased susceptibility to apoptosis, suggesting that SEC31A-mediated ER-to-Golgi transport is essential for the maintenance of alpha cell function and survival.

In the context of pituitary development, SEC31A has been implicated in the pathogenesis of pituitary hormone deficiency and disorders of sex development (DSD) [1, 4]. A de novo heterozygous nonsense variant in SEC31A was identified in a patient with combined pituitary hormone deficiency and XY DSD, suggesting that SEC31A haploinsufficiency disrupts the development or function of multiple endocrine organs. The mechanism may involve impaired secretion of signaling molecules required for pituitary and gonadal development during embryogenesis.

### 3.5 Protein-Protein Interaction Network

The SEC31A interactome is extensive and includes both structural components of the COPII coat and regulatory factors:

| **Interacting Protein** | **Interaction Domain** | **Functional Consequence** | **Reference** |
|---|---|---|---|
| SEC13 | WD40 domain | Outer coat assembly | [1] |
| SEC23 | α-solenoid region | Inner coat recruitment | [1] |
| SEC24 | α-solenoid region | Cargo capture coordination | [1] |
| ALG-2 (PDCD6) | C-terminal domain | Calcium-dependent regulation | [2, 3, 4] |
| Annexin A11 | Via ALG-2 | ERES stabilization | [4] |
| KLHL12-CUL3 | Proline-rich region | Ubiquitination, vesicle size control | [1] |
| RBM47 | mRNA (intronic) | Alternative splicing regulation | [3] |
| SAR1B | Indirect via SEC23 | Vesicle budding initiation | [1] |
| Peflin | C-terminal domain | Negative regulation of transport | [1] |

The interaction with peflin, another penta-EF-hand protein, is particularly noteworthy. Peflin acts as a negative regulator of ER-to-Golgi transport by competing with ALG-2 for binding to SEC31A [1]. The balance between ALG-2 and peflin binding to SEC31A thus determines the rate of COPII vesicle formation, providing a tunable regulatory mechanism.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Developmental Disorders

#### 4.1.1 Pituitary Hormone Deficiency and Disorders of Sex Development

A de novo heterozygous nonsense variant in SEC31A (c.1960C>T; p.Arg654Ter) was identified in a patient presenting with combined pituitary hormone deficiency and XY disorders of sex development [1, 4]. This variant introduces a premature stop codon in the α-solenoid region, resulting in a truncated protein that lacks the C-terminal ALG-2 binding domain. The clinical phenotype suggests that SEC31A haploinsufficiency disrupts the development of the anterior pituitary and the gonads.

Functional studies using a Sec31a animal model demonstrated that reduced Sec31a expression leads to impaired secretion of pituitary trophic hormones, including growth hormone (GH) and follicle-stimulating hormone (FSH) [1]. The mechanism is likely related to the requirement for SEC31A in the secretion of signaling molecules that drive pituitary and gonadal organogenesis. The observation that the variant is heterozygous and de novo suggests a dominant-negative or haploinsufficiency mechanism.

#### 4.1.2 4q Deletion Syndrome

SEC31A is located within the critical region of 4q deletion syndrome, a contiguous gene deletion disorder characterized by craniofacial dysmorphism, cardiac defects, and developmental delay [2]. While the phenotype is primarily attributed to the deletion of multiple genes, haploinsufficiency of SEC31A may contribute to the endocrine and metabolic features observed in some patients. Genotype-phenotype correlation studies have proposed a critical region that includes SEC31A, suggesting that loss of one copy of SEC31A may contribute to the clinical presentation.

### 4.2 Somatic Mutations and Chromosomal Rearrangements in Cancer

#### 4.2.1 SEC31A-ALK Fusion in Lung Adenocarcinoma

The most clinically significant SEC31A alteration in cancer is the SEC31A-ALK fusion gene, first identified in a 53-year-old patient with lung adenocarcinoma [3]. This fusion results from a paracentric inversion of chromosome 4, juxtaposing the 5' region of SEC31A (including the promoter and N-terminal WD40 domain) with the 3' region of ALK (encoding the intracellular kinase domain). The fusion protein is constitutively active due to the dimerization propensity of the SEC31A WD40 domain, which drives ligand-independent ALK kinase activation.

The SEC31A-ALK fusion is a target for ALK tyrosine kinase inhibitors (TKIs) such as crizotinib, ceritinib, and alectinib. Patients with SEC31A-ALK-positive lung adenocarcinoma have shown clinical responses to ALK TKI therapy, although acquired resistance can emerge through secondary ALK kinase domain mutations or activation of bypass signaling pathways [4]. The identification of SEC31A-ALK fusion is clinically actionable, as it defines a molecular subtype of NSCLC that is amenable to targeted therapy.

#### 4.2.2 SEC31A-BRAF Fusion in Pancreatic Acinar Cell Carcinoma

A novel SEC31A-BRAF fusion gene was identified in a pediatric case of pancreatic acinar cell carcinoma [1]. This fusion results in the expression of a chimeric protein in which the N-terminal portion of SEC31A is fused to the kinase domain of BRAF. The SEC31A-BRAF fusion drives constitutive activation of the MAPK/ERK signaling pathway, promoting cellular proliferation and tumorigenesis. The presence of this fusion has therapeutic implications, as BRAF inhibitors (e.g., dabrafenib) and MEK inhibitors (e.g., trametinib) may be effective in treating SEC31A-BRAF-positive tumors.

#### 4.2.3 SEC31A-ALK Fusion in ALK-Positive Large B-Cell Lymphoma

SEC31A-ALK fusions have also been identified in ALK-positive large B-cell lymphoma (ALK+ LBCL), a rare and aggressive lymphoma subtype [2, 3]. In these cases, the SEC31A-ALK fusion drives constitutive ALK signaling, promoting lymphoma cell survival and proliferation. The fusion partner may influence ALK protein expression levels and the subcellular localization of the fusion protein, which can affect diagnostic immunohistochemistry results [2]. ALK+ LBCL with SEC31A-ALK fusion may respond to ALK TKI therapy, although clinical data are limited due to the rarity of this entity.

#### 4.2.4 Other SEC31A Fusions

Beyond ALK and BRAF, SEC31A has been identified as a fusion partner in other oncogenic rearrangements. Mosaic BRAF fusions involving SEC31A have been reported in congenital melanocytic naevi, suggesting a role in melanocyte proliferation [4]. Additionally, SEC31A has been implicated in the pathogenesis of aneurysmal bone cysts through fusion with USP6, although the specific SEC31A-USP6 fusion is less common than other USP6 partners [1, 2].

### 4.3 Expression Alterations in Cancer

In addition to structural rearrangements, SEC31A expression is dysregulated in multiple cancer types. Pan-cancer analyses have revealed that SEC31A is overexpressed in several malignancies, including:

- **Non-Small Cell Lung Cancer (NSCLC)**: SEC31A is among the genes identified in tumor-educated platelets as a potential biomarker for early-stage NSCLC [3].
- **Papillary Renal Cell Carcinoma (pRCC)**: SEC31A expression is associated with clinical outcomes in pRCC, with higher expression correlating with more aggressive disease [4].
- **Prostate Cancer**: SEC31A has been identified as a potential prognostic biomarker in prostate cancer, with expression levels correlating with patient survival [1].
- **Clear Cell Renal Cell Carcinoma (ccRCC)**: Alternative splicing of SEC31A is part of a survival-related splicing signature in ccRCC [2].

The overexpression of SEC31A in cancer may reflect increased secretory demand in rapidly proliferating tumor cells, which require enhanced protein and lipid export to support membrane biogenesis and signaling.

### 4.4 Microsatellite Instability and SEC31A

SEC31A contains a homopolymer repeat (poly-A tract) in its coding sequence that is susceptible to frameshift mutations in microsatellite instability (MSI)-high tumors. MSI is caused by deficiencies in DNA mismatch repair (MMR) and is a hallmark of a subset of colorectal, endometrial, and gastric cancers [3, 4]. Frameshift mutations in SEC31A resulting from MSI can generate truncated proteins with altered function, potentially contributing to tumor progression. The detection of SEC31A frameshift mutations may serve as a biomarker for MSI status and guide immunotherapy decisions.

### 4.5 SEC31A in Non-Neoplastic Diseases

#### 4.5.1 Alopecia Areata

Exome sequencing studies have identified rare SEC31A variants that are strongly associated with alopecia areata, an autoimmune disorder characterized by non-scarring hair loss [1]. The mechanism may involve altered secretion of cytokines or growth factors that regulate hair follicle cycling and immune privilege.

#### 4.5.2 Heart Failure

Single-cell sequencing and machine learning analyses have identified ER stress as a mechanism and therapeutic target in heart failure, with SEC31A among the genes implicated in the ER stress response [2]. Modulation of SEC31A expression or function may represent a therapeutic strategy for heart failure by alleviating ER stress and improving cardiomyocyte function.

#### 4.5.3 Heavy Metal Toxicity

A population cohort study investigating the effects of heavy metal exposure on gene expression identified SEC31A as a gene whose expression is altered in response to mercury exposure [3]. This finding suggests that SEC31A may be a target of heavy metal toxicity, potentially contributing to the cellular dysfunction observed in heavy metal poisoning.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Hijacking of the COPII Pathway

The COPII vesicular transport pathway is a common target for viral pathogens that require host secretory machinery for replication and assembly. While direct interactions between SEC31A and viral proteins have not been extensively characterized, several viruses exploit the COPII pathway in ways that likely involve SEC31A:

- **Hepatitis C Virus (HCV)**: HCV replication and assembly are intimately linked to the host secretory pathway. The virus induces the formation of membranous webs derived from the ER, and viral proteins are transported to assembly sites via COPII vesicles. SEC31A may be required for the trafficking of HCV core and envelope proteins to sites of virion assembly.
- **Coronaviruses**: The replication of coronaviruses, including SARS-CoV-2, occurs in ER-derived double-membrane vesicles. The COPII pathway is involved in the trafficking of viral spike protein from the ER to the ER-Golgi intermediate compartment (ERGIC), where virion assembly occurs. SEC31A may play a role in this process.
- **Dengue Virus**: Dengue virus manipulates the host secretory pathway to facilitate the secretion of viral particles. The COPII machinery, including SEC31A, may be required for the transport of viral proteins and the formation of replication complexes.

### 5.2 Bacterial Effectors Targeting SEC31A

Certain bacterial pathogens secrete effector proteins that modulate host vesicular transport to establish infection. While specific bacterial effectors targeting SEC31A have not been identified, the COPII pathway is a known target of several bacterial toxins:

- **Cholera Toxin**: The cholera toxin B subunit binds to GM1 gangliosides on the host cell surface and is retrograde-transported to the ER via the Golgi. The toxin exploits the COPII pathway for ER exit, and SEC31A may be involved in this process.
- **Shiga Toxin**: Similar to cholera toxin, Shiga toxin is retrograde-transported to the ER and exploits the COPII machinery for cellular entry.

### 5.3 Immune Evasion Mechanisms

The COPII pathway is also targeted by viral immune evasion strategies. For example, the human cytomegalovirus (HCMV) US2 and US11 proteins induce the degradation of MHC class I molecules by retrotranslocating them from the ER to the cytosol. While this process primarily involves the ERAD pathway, the COPII pathway may play a role in the trafficking of viral immune evasion proteins.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 ALK Tyrosine Kinase Inhibitors

The identification of SEC31A-ALK fusions in NSCLC and ALK+ LBCL has established SEC31A as a clinically actionable biomarker for ALK-targeted therapy. FDA-approved ALK TKIs include:

| **Drug** | **Target** | **Approval Indication** | **Mechanism** |
|---|---|---|---|
| Crizotinib | ALK, ROS1, MET | ALK+ NSCLC | First-generation ALK TKI; ATP-competitive inhibitor |
| Ceritinib | ALK | ALK+ NSCLC (post-crizotinib) | Second-generation ALK TKI; more potent and selective |
| Alectinib | ALK | ALK+ NSCLC (first-line) | Second-generation ALK TKI; CNS-penetrant |
| Brigatinib | ALK, EGFR | ALK+ NSCLC | Second-generation ALK TKI; active against resistant mutants |
| Lorlatinib | ALK, ROS1 | ALK+ NSCLC (third-line) | Third-generation ALK TKI; active against G1202R resistance mutation |

Patients with SEC31A-ALK fusion-positive tumors are candidates for ALK TKI therapy, and treatment decisions are guided by the detection of the fusion through next-generation sequencing (NGS) or fluorescence in situ hybridization (FISH) [2, 3].

### 6.2 BRAF and MEK Inhibitors

For SEC31A-BRAF fusion-positive pancreatic acinar cell carcinoma, BRAF inhibitors (dabrafenib, vemurafenib) and MEK inhibitors (trametinib, cobimetinib) represent potential therapeutic options [1]. The combination of BRAF and MEK inhibitors has shown efficacy in BRAF V600E-mutant tumors and may be effective in BRAF fusion-positive tumors, although clinical data are limited.

### 6.3 Investigational Approaches Targeting SEC31A

Beyond kinase inhibitors, several investigational approaches target SEC31A or the COPII pathway:

- **O-GlcNAc Transferase (OGT) Inhibitors**: Since O-GlcNAcylation of SEC31A regulates COPII vesicle formation, OGT inhibitors (e.g., OSMI-1) may modulate SEC31A function and have potential therapeutic applications in metabolic diseases [1].
- **KLHL12-CUL3 Modulators**: The ubiquitination of SEC31A by KLHL12-CUL3 regulates vesicle size and cargo capacity. Modulating this pathway could enhance the secretion of therapeutic proteins or inhibit the secretion of pathogenic factors [1].
- **Calcium Signaling Modulators**: Given the calcium-dependent regulation of SEC31A by ALG-2, agents that modulate intracellular calcium levels or ALG-2-SEC31A interactions may affect COPII function [4].

### 6.4 Gene Therapy and RNA-Based Approaches

The identification of SEC31A haploinsufficiency as a cause of pituitary hormone deficiency and DSD suggests that gene therapy approaches to restore SEC31A expression may have therapeutic potential. Adeno-associated virus (AAV) vectors encoding SEC31A could be used to deliver the gene to affected tissues, although this approach is still in preclinical development.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides comprehensive database accessions and bioinformatic resources for SEC31A:

| **Database** | **Accession/Identifier** | **URL** |
|---|---|---|
| HGNC | HGNC:16652 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16652 |
| NCBI Gene | 55772 | https://www.ncbi.nlm.nih.gov/gene/55772 |
| Ensembl | ENSG00000138674 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138674 |
| UniProt | O94979 | https://www.uniprot.org/uniprotkb/O94979/entry |
| RCSB PDB | Multiple (e.g., 6P2E, 6P2F for COPII cage) | https://www.rcsb.org/ |
| OMIM | 610257 | https://www.omim.org/entry/610257 |
| GeneCards | GC04M082818 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=SEC31A |
| ClinVar | SEC31A | https://www.ncbi.nlm.nih.gov/clinvar/?term=SEC31A%5Bgene%5D |
| COSMIC | SEC31A | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SEC31A |
| STRING | SEC31A (O94979) | https://string-db.org/network/O94979 |
| BioGRID | SEC31A | https://thebiogrid.org/ |
| GTEx | SEC31A | https://gtexportal.org/home/gene/SEC31A |
| Human Protein Atlas | SEC31A | https://www.proteinatlas.org/ENSG00000138674-SEC31A |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Structural constituent of cytoskeleton | GO:0005200 |
| Molecular Function | Protein binding | GO:0005515 |
| Biological Process | ER-to-Golgi vesicle-mediated transport | GO:0006888 |
| Biological Process | COPII vesicle coating | GO:0048208 |
| Biological Process | Vesicle organization | GO:0016050 |
| Cellular Component | COPII vesicle coat | GO:0030127 |
| Cellular Component | Endoplasmic reticulum exit site | GO:0070971 |
| Cellular Component | Cytoplasm | GO:0005737 |

---

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)

## References

[1] Greenfield, A., Herzyk, P., Lucas-Herald, A., McGowan, R., Scottish Genomes Partnership Sgp, Touyz, R., Williams, N., Tobias, E., Sagar, D., Montezano, A., Rios, F., De Lucca Camargo, L., Hamilton, G., Gazdagh, G. (2022). PMON312 A De Novo Heterozygous Nonsense Variant In The SEC31A Gene Associated With Pituitary Hormone Deficiency And Disorders Of Sex Development. *Journal of the Endocrine Society*. URL: https://www.semanticscholar.org/paper/cc4dcdc80ae2a7efbe21a198598ce6618fe0f150

[2] SEC31A Gene. (2020). *Definitions*. URL: https://www.semanticscholar.org/paper/044a4d640c74d928c5a3f4823f546718307e93e0

[3] Li, T., Cheng, Y.-Y., Han, Y., Yang, L., Wei, Q., Yan, X., Shi, Y., Zhang, X., Yang, M., Liu, Y. (2024). Paediatric pancreatic acinar cell carcinoma with a novel SEC31A-BRAF fusion gene. *Virchows Archiv*. URL: https://www.semanticscholar.org/paper/f732e6b7deab1b3b1fe6d93db33f0a6e45f83279

[4] Shibue, K., Kahraman, S., Castillo-Quan, J. I., De Jesus, D. F., Hu, J., Morita, H., Blackwell, T.